The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Verditek falls on cash shell plans

Wed, 07th Feb 2024 09:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Redx Pharma PLC, up 35% at 27.00 pence, 12-month range 19.00p-60.00p. The clinical-stage biotechnology company signs an agreement to sell Kirsten rat sarcoma virus inhibitor program to Jazz Pharmaceuticals PLC. Redx says it will receive USD10 million upfront, with a potential for up to USD870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities.

----------

AIM - LOSERS

----------

Verditek PLC, down 19% at 0.12p, 12-month range 0.080p-1.90p. The producer of lightweight solar panels agrees terms to sell its solar business to a new company, which will be established by the holders of Verditek's secured convertible loan notes for GBP528,340 in notes and GBP50,000 in cash. Upon disposal, Verditek will be regarded as an AIM rule 15 cash shell. Verditek will therefore need to, within six months, make an acquisition or acquisitions which constitute a reverse takeover. It said that it is currently in discussions with "a group of individuals", who it is proposed would come in as a new management team with a view to completing a fundraise of about GBP300,000. The aim would be to conduct a reverse takeover within 6 months of completion of the disposal. "There is no guarantee that this proposal will proceed as it still at an exploratory stage and the company will update the market with more information as soon as it is available," Veritek adds.

----------

Helium One Global Ltd, down 16% at 1.81p, 12-month range 0.19p-10.30p. The primary helium explorer raises GBP4.7 million through a placing of 313.3 million new shares priced at 1.5p each. The placing price represents a 30% discount to the closing price of 2.16p on Tuesday. The proceeds will provide the company with "sufficient" working capital to progress its planning for the next stage of the work programme in Tanzania. Chief Executive Lorna Blaisse says: "The results that we have achieved from the Itumbula West-1 well, flowing helium to surface in such significant concentrations, has confirmed a globally unique helium producing province. By moving quickly and finalising this company led placing early on, we have been able to strengthen our working capital position, which will enable us to fully focus on the next phase of the company's growth."

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
24 Feb 2016 09:44

Redx Pharma Makes Progress On Gonorrhoea Treatment And Other Drugs

Read more
20 Jan 2016 10:00

Redx Pharma Continues Pipeline Progressing In Maiden Results

Read more
13 Jan 2016 16:00

Earnings, Trading Statements Calendar - Week Ahead

Read more
4 Jan 2016 08:35

New Redx director brings scientific, commercial expertise

(ShareCast News) - Redx announced the appointment of a non-executive director on Monday, with Dr Bernhard Kirschbaum joining the firm's board immediately. The AIM-listed self-described drug discovery and development company said Dr Kirschbaum was bringing with him more than 25 years experience in ph

Read more
3 Dec 2015 07:54

Redx Pharma Identifies New Cancer Drug Development Candidate

Read more
6 Nov 2015 09:42

DIRECTOR DEALINGS: Redx Pharma Chairman, Non-Executives Buy Shares

Read more
1 Oct 2015 07:36

Redx Pharma Says It Made "Good Progress" In Second Half

Read more
3 Sep 2015 08:00

Redx Pharma And Horizon Discovery Collaborating On Cancer Research

Read more
22 Jun 2015 14:17

Redx Pharma enjoys good progress during first-half

Two months after its admission to AIM, Redx Pharma said its first-half results were in line with expectations thanks to progress on potential MRSA drugs. Losses before tax rose 60.5% to £3.26m due to a decrease in grant funding and operating expenses increased 5% to £5.48m. The drug discovery and d

Read more
22 Jun 2015 08:35

Redx Pharma Positive For Full Year, Loss Widens In Maiden Interims

Read more
2 Jun 2015 11:13

Redx Pharma cheers with progress on potential MRSA drug

Redx shares jumped on the news it has reached the pre-clinical development stage with a new anti-infective compound designed to tackle MRSA, the bacteria that causes potentially lethal infections in humans. The pharmaceutical firm said the progress marked a "significant milestone" for its commercial

Read more
2 Jun 2015 07:00

Redx Pharma Progresses To Pre-Clinical Stage With MRSA Treatment

Read more
26 May 2015 07:43

Redx Pharma Identifies Second Drug Development Candidate

Read more
14 May 2015 09:41

Redx Pharma To Launch New Immunology Subsidiary

Read more
14 May 2015 08:55

Redx Pharma Says Third Paper On Antimicrobial Resistance Published

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.